Agents clinically evaluated in patients refractory to ibrutinib
| Agent . | Number of ibrutinib-refractory patients . | Median duration of treatment . | ORR, % . |
|---|---|---|---|
| Venetoclax | 43 | 13 mo | 70 |
| Duvelisib | 6 | 4.1 cycles | 16.6 |
| Entospletinib | 15 | 16 wk | 28* |
| Agent . | Number of ibrutinib-refractory patients . | Median duration of treatment . | ORR, % . |
|---|---|---|---|
| Venetoclax | 43 | 13 mo | 70 |
| Duvelisib | 6 | 4.1 cycles | 16.6 |
| Entospletinib | 15 | 16 wk | 28* |
ORR, overall response rate.
Refers to all prior BTK inhibitor-treated patients, not just those with ibrutinib-refractory disease.